Rocklatan for Glaucoma

This trial explores how Rocklatan eye drops affect blood flow in the eyes of people with glaucoma, a condition that can lead to vision loss. Researchers aim to determine if special devices can detect changes in eye blood flow after using the drops. Participants should have glaucoma in both eyes and have been using latanoprost, a common glaucoma medication, but still experience high eye pressure affecting their daily life. As a Phase 4 trial, this research helps to understand how the already FDA-approved and effective treatment benefits more patients.

The trial does not specify if you need to stop taking your current medications, but it mentions that participants should have been on latanoprost monotherapy (using only one medication) before joining. It's best to discuss with the trial team or your doctor.

Research has shown that Rocklatan, a combination of two medications, is generally safe for treating glaucoma. In studies, Rocklatan proved effective and safe over 12 months, with most side effects being mild. For instance, 59% of patients experienced some eye redness, but only 5% found it bothersome. The FDA has already approved this eye drop for open-angle glaucoma, indicating it has passed important safety tests.¹²³⁴⁵

Rocklatan is unique because it combines two active ingredients, netarsudil and latanoprost, which are both used to lower intraocular pressure in glaucoma patients. Most treatments for glaucoma typically involve using single-agent eye drops, such as prostaglandin analogs or beta-blockers. However, Rocklatan's dual-action formula not only reduces fluid production but also enhances fluid outflow, potentially offering more effective pressure reduction. Researchers are excited about Rocklatan because this combination may provide better control of eye pressure with a single drop, improving convenience and adherence for patients.

Research shows that Rocklatan, which participants in this trial may receive, effectively lowers eye pressure, crucial for treating glaucoma. Studies have found that Rocklatan reduces eye pressure by 1 to 3 mmHg more than using either of its components, netarsudil or latanoprost, alone. This combination treatment is well-tolerated and provides a significant, lasting reduction in eye pressure. The fixed-dose combination of netarsudil and latanoprost in Rocklatan consistently yields better results in lowering eye pressure compared to using each component separately. Overall, Rocklatan has proven effective for managing the eye pressure associated with glaucoma.¹⁶⁷⁸⁹